Atara Biotherapeutics, Inc. (ATRA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Atara Biotherapeutics, Inc. reported revenue of $120.77M, down 6.3% from the prior year. The company was profitable, with a net margin of 27.1%. It held $20.23M in total assets against $58.74M in total liabilities.
Key ratios (FY2025)
29.7%
Operating margin
27.1%
Net margin
-6.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.77M | $128.94M | $8.57M | $63.57M | — | — | — | — | — | — |
| Operating Income | $35.86M | -$83.44M | -$276.01M | -$280.51M | -$340.46M | -$309.05M | -$295.68M | -$237.11M | -$121.53M | -$81.24M |
| Net Income | $32.69M | -$85.40M | -$276.13M | -$228.30M | -$340.14M | -$306.62M | -$290.98M | -$230.70M | -$119.49M | -$79.05M |
| EPS (Diluted) | $2.57 | $-11.41 | $-65.19 | $-2.24 | $-3.63 | $-4.15 | — | — | — | — |
| Total Assets | $20.23M | $109.10M | $165.50M | $376.42M | $468.13M | $588.12M | $342.94M | $391.84M | $217.78M | $263.91M |
| Total Liabilities | $58.74M | $206.38M | $264.74M | $249.78M | $188.51M | $125.78M | $52.16M | $52.98M | $39.91M | $10.18M |
| Shareholders' Equity | -$38.50M | -$97.28M | $99.23M | $126.64M | $279.61M | $462.34M | $290.78M | $339.22M | $177.86M | $253.74M |
| Cash & Equivalents | $8.48M | $25.03M | $25.84M | $92.94M | $106.08M | $200.40M | $74.32M | $60.70M | $79.22M | $47.97M |
| Operating Cash Flow | -$50.94M | -$68.72M | -$192.98M | -$270.43M | -$220.52M | -$180.76M | -$235.63M | -$179.77M | -$87.50M | -$60.02M |
| Capital Expenditures | $0 | $246.0K | $1.22M | $4.19M | $10.58M | $4.51M | $5.73M | $35.92M | $20.23M | $3.02M |
| Shares Outstanding | 7.32M | 5.86M | 4.26M | 95.93M | 91.67M | 83.37M | 56.81M | 45.95M | 30.73M | 28.93M |